Dopamine antagonists for nausea and vomiting: special considerations

Area of Science:

• Pharmacology
• Neuroscience
• Clinical Medicine

Background:

• Dopamine antagonists, notably droperidol, are established treatments for nausea and vomiting (N&V).
• Dopamine's widespread roles in the central nervous system necessitate awareness of potential central nervous system side effects.
• Understanding the risk-benefit profile of dopamine antagonists is crucial for patient safety.

Purpose of the Study:

• To review the efficacy of dopamine antagonists in managing N&V.
• To highlight potential central nervous system alterations associated with dopamine antagonist use.
• To discuss the risk of QT prolongation as a significant adverse event.

Main Methods:

• Literature review of dopamine antagonists for N&V treatment.
• Analysis of reported side effects, focusing on mental status changes and QT prolongation.
• Clinical considerations for managing high-dose administration and adverse events.

Main Results:

• Dopamine antagonists demonstrate effectiveness in treating N&V.
• Alterations in mental status are an expected side effect, particularly at higher dosages.
• QT prolongation is an infrequent but serious adverse event, especially in non-chemotherapy settings.

Conclusions:

• Droperidol and similar agents are valuable for N&V management.
• Clinicians must monitor for and be prepared to manage central nervous system effects.
• Vigilance for and prompt treatment of QT prolongation are essential, especially with higher doses or specific indications.